Stock EVGN EVOGENE LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Evogene Ltd.

Equities

EVGN

IL0011050551

Market Closed - TEL AVIV STOCK EXCHANGE
Other stock markets
 10:31:09 2024-05-02 am EDT 		5-day change 1st Jan Change
277.3 ILa +3.97% Intraday chart for Evogene Ltd. +8.70% -7.51%
Apr. 02 Evogene Ltd. and The Kitchen FoodTech Hub Establishes Finally Foods Ltd CI
Mar. 20 Evogene Receives Minimum Bid Price Non-Compliance Notice From Nasdaq MT

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • The company has insufficient levels of profitability.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
EVOGENE LTD. Stock Evogene Ltd.
-7.51% 37.69M - -
MODERNA, INC. Stock Moderna, Inc.
+25.69% 48.09B
B-
LONZA GROUP AG Stock Lonza Group AG
+46.90% 40.62B
A
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-3.46% 40.43B
B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.36B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+9.17% 24.89B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-20.42% 19.01B
B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+28.07% 12.09B
C+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.17% 11.88B
B+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-1.24% 11.8B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. EVGN Stock
  4. Ratings Evogene Ltd.